Opinion

Video

Financial Considerations Influencing Treatment Strategies in PNH Treatment Pathway

Author(s):

Ryan Haumschild, PharmD, MS, MBA,Jamie L. Koprivnikar, MD

The panelists provide their final thoughts, highlighting financial considerations in PNH treatment.

Video content above is prompted by the following question:

  • How do financial considerations influence your treatment decision-making process?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!
Related Videos
5 experts in this video
5 experts in this video
Related Content
Acute myeloid leukemia cells | Image credit: LASZLO - stock.adobe.com
June 12th 2025

Revumenib Shows Efficacy in Patients With AML and Genetic Alterations

Laura Joszt, MA
Revumenib shows promise for high-risk patients with acute myeloid leukemia (AML) with specific genetic mutations, demonstrating efficacy with no new safety signals.
Managed Care Cast Presents: Challenges of Diagnosing and Managing PNH
July 16th 2024

Managed Care Cast Presents: Challenges of Diagnosing and Managing PNH

A trio of experts discuss the challenges of diagnosing and managing paroxysmal nocturnal hemoglobinuria (PNH), a rare and life-threatening disorder.
Mansi Shah, MD
June 11th 2025

Stem Cell Transplant Remains Cost-Effective Option for MM: Mansi Shah, MD

Laura Joszt, MA Hayden E. Klein Mansi Shah, MD
Mansi Shah, MD, discusses the role of stem cell transplant in multiple myeloma (MM) and the logistical barriers to wider adoption of bispecific therapies.
Podcast: This Week in Managed Care—Pushback on Proposed Payment Rules and Other Health News
September 15th 2018

Podcast: This Week in Managed Care—Pushback on Proposed Payment Rules and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.
The investigators said real-world use of allo-SCT appeared to be receding as a preferred option after relapse, even before these new data. | Image credit: ibreakstock - stock.adobe.com
June 7th 2025

Auto-SCT Superior to Allo-SCT in Relapsed Myeloma After First-Line Auto-SCT

Jared Kaltwasser
A meta-analysis suggests allogeneic stem cell transplantation (allo-SCT) should not be recommended following first-line autologous stem cell transplant (auto-SCT).
The findings show that ctDNA is worthy of additional study as a tool for assessing risk and treatment response in large B-cell lymphoma, the authors concluded. | Image credit: Connect world - stock.adobe.com
June 7th 2025

Biomarker-Adapted Treatment Effective in High-Risk LBCL

Jared Kaltwasser
TP53 aberrations and circulating tumor DNA burden were found to be predictors of poor outcomes in high-risk patients with large B-cell lymphoma.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo